• Phase 2/3 RCT
• Phase 2: Sarilumab in hospitalized patients regardless of disease severity vs. placebo
• Primary outcome of % change in CRP in patients with serum IL-6 > upper limit normal
• Phase 3 Cohort 1: Sarilumab in hospitalized critical infection receiving mechanical ventilation vs. placebo
• Cohort 2: Sarilumab in hospitalized infection receiving mechanical ventilation vs. placebo
•  N = 1912
• Primary outcome of at least 1 point improvement on 7 point clinical scale